Manufacture of atla antibody
    94.
    发明专利
    Manufacture of atla antibody 失效
    ATLA抗体的制备

    公开(公告)号:JPS59150340A

    公开(公告)日:1984-08-28

    申请号:JP2523383

    申请日:1983-02-16

    CPC classification number: C07K14/005 C07K16/1036 C12N2740/14022

    Abstract: PURPOSE:To obtain a novel antibody which reacts specifically to an antigen related to a human T cell leukemia by using an immuno-antigen with a specified peptide as hapten employing a commercial amino acid. CONSTITUTION:In the production of an antibody, a specific amount of an immuno-antigen comprising a composite of a compound selected from peptide related to a human leukemia virus expressed by the formula (where, R represents hydrogen atom or H-Tyr) and a derivative thereof and a carrier is diluted with a saline solution to a proper concentration and mixed with a Freund's adjuvant to adjust a suspension. The suspension is injected subcutaneously into a mammal and thereafter, continuously dosed for 4-6 months to immunize. To sample the antibody, one-two weeks after the final dosage of said suspension, blood is sampled from the annimal immunized and following centrifugal separation, the secrum is separated. Thus, an antibody with a high titer and a high sensitivity can be obtained having an excellent specificity to ATLA, particularly p24.

    Abstract translation: 目的:通过使用具有特定肽的免疫抗原作为使用商业氨基酸的半抗原,获得与人类T细胞白血病相关的抗原特异性反应的新型抗体。 构成:在抗体的制备中,特定量的免疫抗原,其包含选自与由式(其中,R表示氢原子或H-Tyr)表示的人白血病病毒有关的肽的化合物和 衍生物和载体用盐水溶液稀释至适当浓度并与弗氏佐剂混合以调节悬浮液。 将悬浮液皮下注射到哺乳动物中,然后连续给药4-6个月以免疫。 为了在所述悬浮液的最终剂量的一至两周后对抗体进行采样,从最近免疫的和随后的离心分离中取血,分离出secrum。 因此,可以获得具有高滴度和高灵敏度的抗体,其对ATLA具有优异的特异性,特别是p24。

Patent Agency Ranking